|
|
2273 Research Boulevard, Suite 400
Rockville, MD 20850 USA
phone:301-795-1800
fax:301-795-1899
|
|
| Symbol |
EBS |
| Exchange |
NYSE |
| Founded |
1998 |
| Employees |
306 |
|
|
| www.emergentbiosolutions.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics for the immune system |
|
| Management |
| Fuad El-Hibri, Chief Executive Officer and Chairman of the Board of Directors; Daniel J. Abdun-Nabi, President and Chief Operating Officer; R. Don Elsey, Senior Vice President Finance & Administration and Chief Financial Officer; Denise Esposito, Senior Vice President Legal Affairs, General Counsel and Secretary; Mauro Gibellini, Senior Vice President Corporate Affairs |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| anthrax, therapeutic, botulinum, vaccine, biothrax, acquired Trubion Pharmaceuticals |
|
|
|
|
|
|
| Description |
|
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body�s immune system to prevent o...
view more
|
|
| Products / Services |
Anthrax Vaccine Adsorbed, (BioThraxo) is a sterile, milky-white suspension (when mixed) made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The production cultures are grown in a chemically defined protein-free medium consisting of a mixture of amino acids, vitamins, inorganic salts and sugars. The final product, prepared from the sterile filtrate culture fluid contains proteins, including the 83kDa protective antigen protein, released during the growth period. The final product contains no dead or live bacteria. The final product is formulated to contain 1.2 mg/mL aluminum, added as aluminum hydroxide in 0.85% sodium chloride. The product is formulated to contain 25 /mL benzethonium chloride and 100/mL formaldehyde, added as preservatives.
|
|
| Technology / Differentiation |
| Immunogenicity- Designed to induce mucosal and systemic immune response, Versatility- All-purpose vaccine vector technology designed to deliver a wide range of antigens to prevent/ treat numerous diseases |
|
| Market / Customers |
There is little experience, especially in the United States, with the deliberate release of biological agents to cause major disease outbreaks. However, events of recent years have focused attention on the increasing possibility of such incidents, particularly to the possibility of terrorist incidents aimed at the civilian population.
|
|
| Status |
| Over 2,000,000 doses have been given to over 500,000 service men and women. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members